Singapore, Singapore, 1st Aug 2025 – CytoNiche Biotech, a leader in 3D cell mass production technology, has opened its 3D FloTrix™ Experience Center in Singapore. This milestone marks a key step in the company’s global expansion, showcasing the technology behind China’s first approved stem cell therapy, with costs estimated by the company to be a fraction of comparable Western therapies.
The high cost of stem cell therapies remains a global barrier. For example, stem cell therapy costs $1.55 million per treatment on the market, while China’s approved stem cell injection, approved in 2025, costs approximately 158,400 CNY (~$21,600) per course (source: company annual report). CytoNiche’s 3D FloTrix™ platform enables this cost reduction through GMP-grade dissolvable microcarriers and an automated 3D cell production system, validated by clinical trials in China and supporting the world’s first commercially scaled 3D-manufactured stem cell therapy.
Singapore: A Hub for Global Expansion
The 3D FloTrix™ Experience Center serves as a global headquarters for partners, a technology showcase, and a regional training hub, accelerating the adoption of cost-effective stem cell manufacturing. “Singapore’s robust biotech ecosystem and transparent regulatory environment make it an ideal launchpad,” said Dr. Yan Xiaojun, Chief Technology Officer. “We aim to enhance access to cell therapies through advanced 3D culture systems.”
At the opening, Chief Scientist Professor Du Yanan reflected on CytoNiche’s journey from a 2018 startup to enabling China’s first approved stem cell therapy: “Two decades ago, I studied in Singapore. Today, we return with a solution to transform global cell therapy manufacturing.” The ceremony, held at 1:18 p.m., featured a ribbon-cutting by Professor Du Yanan, Dr. Liu Wei, and Dr. Yan Xiaojun, followed by a symbolic “Ong Lai” pineapple toss for prosperity. CytoNiche signed four cooperation agreements with companies in South Korea, Thailand, India, and Malaysia to distribute 3D FloTrix™ technology and consumables.
Looking Ahead
CytoNiche plans to expand its global client base and lower cell therapy costs through automated biomanufacturing platforms. “This isn’t just about opening a center—it’s a step toward making regenerative medicine globally accessible,” said Professor Du.
About CytoNiche Biotech
Founded in 2018, CytoNiche Biotech specializes in 3D cell mass production systems. Its 3D FloTrix™ platform supports cell therapy expansion, harvesting, and processing with GMP-grade dissolvable microcarriers, serum-free media, and automated bioreactors. For more, visit: https://en.cytoniche.com.
Media Contact
Organization: CytoNiche Biotech Pte. Ltd.
Contact Person Name: Sun Yuan
Website: https://www.cytoniche.com/
Email: marketing@cytoniche.com
